8-K ·Filed Oct 22, 2026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral
Routine board appointment with no immediate catalyst. Monitor upcoming quarterly filings for any strategic shifts or pipeline updates that could affect the stock.
Latest settled — T+1d ⚠ clustered
MBX ▼ -3.88% at T+1d
NEUTRAL call -3.88% · α vs SPY -3.36% · entry $50.46 → $48.50
T+1d
-3.88%
call -3.88% · α -3.36%
$48.50
settled 3d ago
T+5d
Pending
in 3d
T+20d
Pending
in 24d
T+60d
Pending
in 3mo
Price Chart
Loading chart...
Executive Summary
MBX Biosciences appointed Peter Radovich as an independent Class I director, effective October 20, 2026, expanding the board to eight members. The appointment is a routine governance event with no financial or operational impact disclosed.
Key Facts
- Peter Radovich appointed as independent Class I director effective October 20, 2026.
- Board size set to eight directors.
- Radovich receives standard non-employee director compensation: initial option for 18,200 shares and cash compensation per the company's Non-Employee Director Compensation Policy.
- No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.
Financial Impact
Routine director appointment; no material financial impact disclosed.
Risk Factors
- No material risks identified from this filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-428367 |
| Document: 0001193125-26-428367-index-headers.html | 0001193125-26-428367 |
| Document: 0001193125-26-428367-index.html | 0001193125-26-428367 |
| Document: 0001193125-26-428367.txt | 0001193125-26-428367 |
27 reports for MBX
70% Hit rate @ T+1 Went positive at some point 8 of 10 best @ T+60▲ +85.57%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 3 | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $50.29 (−0.34%) |
Oct 22, 2026 4d ago | 8-K | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $50.29 (−0.34%) |
Aug 27, 2026 8w ago | Press Release | $66.39 $63.00 | ▼ −5.11% | ▼ −4.88% | $50.29 (−24.25%) |
Aug 17, 2026 10w ago | 144 | $68.25 $66.52 | ▼ −2.53% | ▼ −1.86% | $50.29 (−26.32%) |
Aug 6, 2026 11w ago | 8-K | $67.11 $67.82 | ▲ +1.06% | ▲ +0.45% | $50.29 (−25.06%) |
Jun 12, 2026 19w ago | 8-K | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $50.29 (+41.62%) |
Jun 12, 2026 19w ago | Press Release | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $50.29 (+41.62%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $50.29 (+35.01%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $50.29 (+35.01%) |
Jun 10, 2026 19w ago | 144 | $30.99 $37.25 | ▲ +20.20% | ▲ +18.50% | $50.29 (+62.28%) |
Showing 10 of 27
US Market Status
Market Closed — Opens Tue (< 1m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers